Industry Press Releases

Moberg Pharma announces Issue of European Patent for Kerasal Nail

Thursday, May 28, 2015
Pressreleases

Moberg Pharma AB today announced that the European Patent Office has issued patent no. 2,777,689 for an improved formulation of Moberg Pharma’s market-leading OTC product for the treatment of fungal nails, sold in the U.S. under the Kerasal Nail® brand. The patent expires in 2034.The new European patent comprises composition of matter claims directed to novel formulations for topical application to the nails. The corresponding U.S. patent was also granted earlier this spring and Moberg Pharma is pursuing patent approval in all major territories.

“The granted Kerasal Nail patents provide long-term intellectual property protection for our flagship product. It also reconfirms our commitment to bringing innovation to underserved niches and our long term goal to be the leading player in nail fungus,” said Peter Wolpert, CEO of Moberg Pharma AB.

About Nail Fungus and Kerasal Nail®

Approximately 10% of the general population suffers from onychomycosis (nail fungus) and a majority of those afflicted go untreated. Kerasal Nail® is an OTC (over-the-counter) product based on a novel formulation of proven compounds and is clinically proven to rapidly improve the appearance of unsightly fungal nails. Kerasal Nail is applied to the damaged nail using a no-mess, silicone tip applicator. Its efficacy and safety have been documented in several clinical trials including more than 600 patients. Kerasal Nail has a unique rapid mechanism of action and has demonstrated compelling treatment results, including visible improvement within 2-4 weeks.

About this information

Moberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8.30 a.m. (CET) on May 28, 2015.

About Moberg Pharma

Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with OTC sales operations in the U.S. and a distributor network in more than 40 countries. The company’s portfolio includes the OTC brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish®, and Fergon®. Kerasal Nail® (Emtrix® or Nalox™ in certain markets) is a leading OTC treatment of nail disorders in the U.S., Canada and several EU markets and is currently being launched in Southeast Asia. The company is growing organically as well as through acquisitions. Internal development programs focuses on innovative drug delivery of proven compounds and include two phase II assets, MOB-015 (onychomycosis) and BUPI (oral mucositis). Moberg Pharma has offices in Stockholm and New Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB). For further information, please visit: www.mobergpharma.com.

This information was brought to you by Cision http://news.cision.com

Contacts

Moberg Pharma
Peter Wolpert, CEO
Telephone: +46 (0)70 - 735 7135
E-mail: peter.wolpert@mobergpharma.se
or
Anna Ljung, CFO
Telephone: +46 (0)70 - 766 60 30
E-mail: anna.ljung@mobergpharma.se

 

businesswire.com

Other Press Releases